Clicky

Replimune Group, Inc.(REPL)

Description: Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Oncolytic Virus Immunotherapy Products Experimental Cancer Treatments Transgene Sa Rp1

Home Page: www.replimune.com

REPL Technical Analysis

500 Unicorn Park Drive
Woburn, MA 01801
United States
Phone: 781 222 9600


Officers

Name Title
Mr. Philip Astley-Sparke FSA CEO & Director
Dr. Robert Coffin Ph.D. Founder, Pres, Chief R&D Officer and Director
Ms. Tanya N. Lewis M.S. Chief Devel. Operations Officer
Mr. Sushil Patel Ph.D. Chief Commercial Officer
Ms. Jean M. Franchi Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
Dr. Colin A. Love Ph.D. Chief Operating Officer
Dr. Pamela Esposito Ph.D. Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.6145
Price-to-Sales TTM: 0
IPO Date: 2018-07-20
Fiscal Year End: March
Full Time Employees: 206
Back to stocks